A review on nanotechnology based ophthalmic drug delivery system
Abstract
The field of ophthalmic drug delivery has witnessed significant advancements through the integration of nanotechnology. Despite having numerous conventional dosage forms employed in the ocular drug delivery system the problem of less bioavailability and less retention time is a significant concern. Along with it there are various barriers also involved that affects the drug permeability, solubility due to the lower residence time of the drug on ocular surface. To overcome these problems the nanotechnology approach can be most suitable. All nanocarriers have emerged as a promising career for precise drug targeting to ocular tissues. Their small size, biocompatibility and surface modification enable improved drug solubility, sustained release and enhanced bioavailability. Moreover nanotechnology facilitates the incorporation of therapeutic agents for various ocular conditions, including glaucoma, macular degeneration and infections. These advancements aim to overcome the challenges and barriers in ocular drug delivery system. This review underscores the immense potential of nanotechnology to revolutionize ophthalmic drug delivery, offering the prospect of more efficient and patient-friendly treatments for ophthalmic disorders.
Keywords: Ocular drug delivery, Nanotechnology, Nanocarriers, Intraocular pressure, Ophthalmic barriers
Keywords:
Ocular drug delivery, Nanotechnology, Nanocarriers, Intraocular pressure, Ophthalmic barriersDOI
https://doi.org/10.22270/jddt.v13i12.6337References
Ahmed S, Amin MM, Sayed S. Ocular Drug Delivery: a Comprehensive Review. AAPS PharmSciTech. 2023 Feb 14;24(2):66. https://doi.org/10.1208/s12249-023-02516-9 PMid:36788150
Willoughby CE, Ponzin D, Ferrari S, Lobo A, Landau K, Omidi Y. Anatomy and physiology of the human eye: effects of mucopolysaccharidoses disease on structure and function - a review. Clin Experiment Ophthalmol. 2010 Aug;38(s1):2-11. https://doi.org/10.1111/j.1442-9071.2010.02363.x
Wadhwa S, Paliwal R, Paliwal S, Vyas S. Nanocarriers in Ocular Drug Delivery: An Update Review. Curr Pharm Des. 2009 Aug 1;15(23):2724-50. https://doi.org/10.2174/138161209788923886 PMid:19689343
Wankhede TM, Wankhede AM. Ocular Drug Delivery System: Review. 21.
Rahul J, Namrata H, Raykar M, Goi H. Occular Drug Delivery System. 2022;10(3).
Raj VK, Mazumder R, Madhra M. OCULAR DRUG DELIVERY SYSTEM: CHALLENGES AND APPROACHES. Int J Appl Pharm. 2020 Aug 11;49-57. https://doi.org/10.22159/ijap.2020v12i5.38762
Lee DA, Higginbotham EJ. Glaucoma and its treatment: A review. Am J Health Syst Pharm. 2005 Apr 1;62(7):691-9. https://doi.org/10.1093/ajhp/62.7.691 PMid:15790795
Alasil T, Wang K, Yu F, Field MG, Lee H, Baniasadi N, et al. Correlation of Retinal Nerve Fiber Layer Thickness and Visual Fields in Glaucoma: A Broken Stick Model. Am J Ophthalmol. 2014 May;157(5):953-959.e2. https://doi.org/10.1016/j.ajo.2014.01.014 PMCid:PMC4423422
Grzybowski A, Och M, Kanclerz P, Leffler C, De Moraes CG. Primary Open Angle Glaucoma and Vascular Risk Factors: A Review of Population Based Studies from 1990 to 2019. J Clin Med. 2020 Mar 11;9(3):761. https://doi.org/10.3390/jcm9030761 PMid:32168880 PMCid:PMC7141380
Patel K, Patel S. Angle-closure glaucoma. Dis Mon. 2014 Jun;60(6):254-62. https://doi.org/10.1016/j.disamonth.2014.03.005 PMid:24906670
Wright C, Tawfik MA, Waisbourd M, Katz LJ. Primary angle-closure glaucoma: an update. Acta Ophthalmol (Copenh). 2016 May;94(3):217-25. https://doi.org/10.1111/aos.12784
Qummar S, Khan FG, Shah S, Khan A, Shamshirband S, Rehman ZU, et al. A Deep Learning Ensemble Approach for Diabetic Retinopathy Detection. IEEE Access. 2019;7:150530-9. https://doi.org/10.1109/ACCESS.2019.2947484
Ung L, Bispo PJM, Shanbhag SS, Gilmore MS, Chodosh J. The persistent dilemma of microbial keratitis: Global burden, diagnosis, and antimicrobial resistance. Surv Ophthalmol. 2019 May;64(3):255-71. https://doi.org/10.1016/j.survophthal.2018.12.003 PMid:30590103 PMCid:PMC7021355
Austin A, Lietman T, Rose-Nussbaumer J. Update on the Management of Infectious Keratitis. Ophthalmology. 2017 Nov;124(11):1678-89. https://doi.org/10.1016/j.ophtha.2017.05.012 PMid:28942073 PMCid:PMC5710829
Koganti R, Yadavalli T, Naqvi RA, Shukla D, Naqvi AR. Pathobiology and treatment of viral keratitis. Exp Eye Res. 2021 Apr;205:108483. https://doi.org/10.1016/j.exer.2021.108483 PMid:33556334 PMCid:PMC8043992
Bourcier T, Sauer A, Dory A, Denis J, Sabou M. Fungal keratitis. J Fr Ophtalmol. 2017 Nov;40(9):e307-13. https://doi.org/10.1016/j.jfo.2017.08.001 PMid:28987448
Azari AA, Barney NP. Conjunctivitis: A Systematic Review of Diagnosis and Treatment. JAMA. 2013 Oct 23;310(16):1721. https://doi.org/10.1001/jama.2013.280318 PMid:24150468 PMCid:PMC4049531
Høvding G. Acute bacterial conjunctivitis. Acta Ophthalmol (Copenh). 2008 Jun 28;86(1):5-17. https://doi.org/10.1111/j.1600-0420.2007.01006.x PMid:17970823
Gupta V, Rajagopala M, Ravishankar B. Etiopathogenesis of cataract: An appraisal. Indian J Ophthalmol. 2014;62(2):103. https://doi.org/10.4103/0301-4738.121141 PMid:24618482 PMCid:PMC4005220
Allen D, Vasavada A. Cataract and surgery for cataract. BMJ. 2006 Jul 15;333(7559):128-32. https://doi.org/10.1136/bmj.333.7559.128 PMid:16840470 PMCid:PMC1502210
Lang JC. Ocular drug delivery conventional ocular formulations. Adv Drug Deliv Rev. 1995 Aug;16(1):39-43. https://doi.org/10.1016/0169-409X(95)00012-V
Sultana Y, Jain R, Aqil M, Ali A. Review of Ocular Drug Delivery. Curr Drug Deliv. 2006 Apr 1;3(2):207-17. https://doi.org/10.2174/156720106776359186 PMid:16611007
Kumar A, Malviya R, Sharma PK. Recent Trends in Ocular Drug Delivery: A Short Review. 2011;
Majeed A, Khan NA. Ocular in situ gel: An overview. J Drug Deliv Ther. 2019 Jan 15;9(1):337-47. https://doi.org/10.22270/jddt.v9i1.2231
Sahoo SK, Labhasetwar V. Nanotech approaches to drug delivery and imaging. Drug Discov Today. 2003 Dec;8(24):1112-20. https://doi.org/10.1016/S1359-6446(03)02903-9 PMid:14678737
Mudgil M, Gupta N, Nagpal M, Pawar P. NANOTECHNOLOGY: A NEW APPROACH FOR OCULAR DRUG DELIVERY SYSTEM. 4(2).
Liu S, Jones L, Gu FX. Nanomaterials for Ocular Drug Delivery. Macromol Biosci. 2012 May;12(5):608-20. https://doi.org/10.1002/mabi.201100419 PMid:22508445
Sharma A. Liposomes in drug delivery: Progress and limitations. Int J Pharm. 1997 Aug 26;154(2):123-40. https://doi.org/10.1016/S0378-5173(97)00135-X
Maurer N, Fenske DB, Cullis PR. Developments in liposomal drug delivery systems. Expert Opin Biol Ther. 2001 Nov;1(6):923-47. https://doi.org/10.1517/14712598.1.6.923 PMid:11728226
Samad A, Sultana Y, Aqil M. Liposomal Drug Delivery Systems: An Update Review. Curr Drug Deliv. 2007 Oct 1;4(4):297-305. https://doi.org/10.2174/156720107782151269 PMid:17979650
Meisner D, Mezei M. Liposome ocular delivery systems. Adv Drug Deliv Rev. 1995 Aug;16(1):75-93. https://doi.org/10.1016/0169-409X(95)00016-Z
Sahoo S, Dilnawaz F, Krishnakumar S. Nanotechnology in ocular drug delivery. Drug Discov Today. 2008 Feb;13(3-4):144-51. https://doi.org/10.1016/j.drudis.2007.10.021 PMid:18275912
Law SL, Huang KJ, Chiang CH. Acyclovir-containing liposomes for potential ocular delivery Corneal penetration and absorption. J Controlled Release. 2000; https://doi.org/10.1016/S0168-3659(99)00192-3 PMid:10640587
Khosa A, Reddi S, Saha RN. Nanostructured lipid carriers for site-specific drug delivery. Biomed Pharmacother. 2018 Jul;103:598-613. https://doi.org/10.1016/j.biopha.2018.04.055 PMid:29677547
Salvi VR, Pawar P. Nanostructured lipid carriers (NLC) system: A novel drug targeting carrier. J Drug Deliv Sci Technol. 2019 Jun;51:255-67.
https://doi.org/10.1016/j.jddst.2019.02.017
Obeidat WM, Schwabe K, Müller RH, Keck CM. Preservation of nanostructured lipid carriers (NLC). Eur J Pharm Biopharm. 2010 Sep;76(1):56-67. https://doi.org/10.1016/j.ejpb.2010.05.001 PMid:20452422
Li X, Nie S fang, Kong J, Li N, Ju C yi, Pan W san. A controlled-release ocular delivery system for ibuprofen based on nanostructured lipid carriers. Int J Pharm. 2008 Nov;363(1-2):177-82. https://doi.org/10.1016/j.ijpharm.2008.07.017 PMid:18706987
Araújo J, Nikolic S, Egea MA, Souto EB, Garcia ML. Nanostructured lipid carriers for triamcinolone acetonide delivery to the posterior segment of the eye. Colloids Surf B Biointerfaces. 2011 Nov;88(1):150-7. https://doi.org/10.1016/j.colsurfb.2011.06.025 PMid:21764568
Nikam PL. NANOSPONGES: A BENEFICATION FOR NOVEL DRUG DELIVERY. World J Pharm Res. 9(5).
Shringirishi M, Prajapati SK, Mahor A, Alok S, Yadav P, Verma A. Nanosponges: a potential nanocarrier for novel drug delivery-a review. Asian Pac J Trop Dis. 2014 Sep;4:S519-26. https://doi.org/10.1016/S2222-1808(14)60667-8
Bhowmik H, Venkatesh DN, Kuila A, Kumar KH. NANOSPONGES: A REVIEW. Int J Appl Pharm. 2018 Jul 7;10(4):1. https://doi.org/10.22159/ijap.2018v10i4.25026
Pillai MK, Jain P, Pillai S. Fabrication and evaluation of nanosponges of besifloxacin hydrochloride for ocular drug delivery. J Med Pharm Allied Sci. 2022 Mar 30;11(2):4657-60. https://doi.org/10.55522/jmpas.V11I2.2586
Diebold Y, Jarrín M, Sáez V, Carvalho ELS, Orea M, Calonge M, et al. Ocular drug delivery by liposome-chitosan nanoparticle complexes (LCS-NP). Biomaterials. 2007 Mar;28(8):1553-64. https://doi.org/10.1016/j.biomaterials.2006.11.028 PMid:17169422
Patel A. Ocular drug delivery systems: An overview. World J Pharmacol. 2013;2(2):47. https://doi.org/10.5497/wjp.v2.i2.47 PMid:25590022 PMCid:PMC4289909
Araújo J, Vega E, Lopes C, Egea MA, Garcia ML, Souto EB. Effect of polymer viscosity on physicochemical properties and ocular tolerance of FB-loaded PLGA nanospheres. Colloids Surf B Biointerfaces. 2009 Aug;72(1):48-56. https://doi.org/10.1016/j.colsurfb.2009.03.028 PMid:19403277
Garhwal R, Shady SF, Ellis EJ, Ellis JY, Leahy CD, McCarthy SP, et al. Sustained Ocular Delivery of Ciprofloxacin Using Nanospheres and Conventional Contact Lens Materials. Investig Opthalmology Vis Sci. 2012 Mar 13;53(3):1341. https://doi.org/10.1167/iovs.11-8215 PMid:22266514 PMCid:PMC3339908
Prajapati SK, Maurya SD, Das MK, Tilak VK, Verma KK, Dhakar RC, Dendrimers in drug delivery, diagnosis and therapy: basics and potential applications. Journal of Drug Delivery and Therapeutics, 2016;6(1),67-92. https://doi.org/10.22270/jddt.v6i1.1190
Yadav JD, Kulkarni PR, Vaidya KA, Shelke GT. Available online through www.jpronline.info NIOSOMES: A REVIEW. J Pharm Res. 2011;(3).
Lohumi A. A NOVEL DRUG DELIVERY SYSTEM: NIOSOMES REVIEW. J Drug Deliv Ther. 2012;2(5). https://doi.org/10.22270/jddt.v2i5.274
Badri S, P S, Annagowni NR, Lunjala RS, B BN, B SKR, et al. A review on niosomes as novel drug delivary system. Int J Indig Herbs Drugs. 2022 Sep 29;87. https://doi.org/10.46956/ijihd.v7i5.352
Hasan AA. Design and in vitro characterization of small unilamellar niosomes as ophthalmic carrier of dorzolamide hydrochloride. Pharm Dev Technol. 2014 Sep;19(6):748-54. https://doi.org/10.3109/10837450.2013.829095 PMid:23964893
Zubairu Y, Negi LM, Iqbal Z, Talegaonkar S. Design and development of novel bioadhesive niosomal formulation for the transcorneal delivery of anti-infective agent: In-vitro and ex-vivo investigations. Asian J Pharm Sci. 2015 Jul;10(4):322-30. https://doi.org/10.1016/j.ajps.2015.02.001
Maurya SD, Prajapati S, Gupta A, Saxena G, Dhakar RC, Formulation development and evaluation of ethosome of stavudine, Int J Pharm Edu Res, 2010;13:16
Liu Z, Zhang X, Wu H, Li J, Shu L, Liu R, et al. Preparation and evaluation of solid lipid nanoparticles of baicalin for ocular drug delivery system in vitro and in vivo. Drug Dev Ind Pharm. 2011 Apr;37(4):475-81. https://doi.org/10.3109/03639045.2010.522193 PMid:21054217
Kalam MohdA, Sultana Y, Ali A, Aqil Mohd, Mishra AK, Chuttani K. Preparation, characterization, and evaluation of gatifloxacin loaded solid lipid nanoparticles as colloidal ocular drug delivery system. J Drug Target. 2010 Apr;18(3):191-204. https://doi.org/10.3109/10611860903338462 PMid:19839712
Wang F, Chen L, Zhang D, Jiang S, Shi K, Huang Y, et al. Methazolamide-loaded solid lipid nanoparticles modified with low-molecular weight chitosan for the treatment of glaucoma: vitro and vivo study. J Drug Target. 2014 Nov;22(9):849-58. https://doi.org/10.3109/1061186X.2014.939983 PMid:25045926
Abdellatif MM, Josef M, El-Nabarawi MA, Teaima M. Sertaconazole-Nitrate-Loaded Leciplex for Treating Keratomycosis: Optimization Using D-Optimal Design and In Vitro, Ex Vivo, and In Vivo Studies. Pharmaceutics. 2022 Oct 18;14(10):2215. https://doi.org/10.3390/pharmaceutics14102215 PMid:36297650 PMCid:PMC9611087
Ibrahim MM, Abd-Elgawad AEH, Soliman OAE, Jablonski MM. Pharmaceutical Nanotechnology Nanoparticle-Based Topical Ophthalmic Formulations for Sustained Celecoxib Release. J Pharm Sci. 2013 Mar;102(3):1036-53. https://doi.org/10.1002/jps.23417 PMid:23293035
Dave RS, Goostrey TC, Ziolkowska M, Czerny-Holownia S, Hoare T, Sheardown H. Ocular drug delivery to the anterior segment using nanocarriers: A mucoadhesive/mucopenetrative perspective. J Controlled Release. 2021 Aug;336:71-88. https://doi.org/10.1016/j.jconrel.2021.06.011 PMid:34119558
Vaishya RD, Khurana V, Patel S, Mitra AK. Controlled ocular drug delivery with nanomicelles. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2014 Sep;6(5):422-37. https://doi.org/10.1002/wnan.1272 PMid:24888969 PMCid:PMC4155159
Mandal A, Bisht R, Rupenthal ID, Mitra AK. Polymeric micelles for ocular drug delivery: From structural frameworks to recent preclinical studies. J Controlled Release. 2017 Feb;248:96-116. https://doi.org/10.1016/j.jconrel.2017.01.012 PMid:28087407 PMCid:PMC5319397
Hughes P, Olejnik O, Changlin J, Wilson C. Topical and systemic drug delivery to the posterior segments. Adv Drug Deliv Rev. 2005 Dec 13;57(14):2010-32. https://doi.org/10.1016/j.addr.2005.09.004 PMid:16289435
Terreni E, Zucchetti E, Tampucci S, Burgalassi S, Monti D, Chetoni P. Combination of Nanomicellar Technology and In Situ Gelling Polymer as Ocular Drug Delivery System (ODDS) for Cyclosporine-A. Pharmaceutics. 2021 Feb 1;13(2):192. https://doi.org/10.3390/pharmaceutics13020192 PMid:33535607 PMCid:PMC7912864
Mohanty D, Mounika A, Bakshi V, Akiful Haque M, Keshari Sahoo C. Ethosomes: A Novel Approach For Transdermal Drug Delivery. Int J ChemTech Res. 2018;11(8):219-26. https://doi.org/10.20902/IJCTR.2018.110826
Dave V, Kumar D, Lewis S, Paliwal S. Ethosome for enhanced transdermal drug delivery of aceclofenac. Int J Drug Deliv. 2010 Mar 16;2(1):81-92. https://doi.org/10.5138/ijdd.2010.0975.0215.02016
Sun Y, Du L, Yang M, Li Q, Jia X, Li Q, et al. Brain-targeted drug delivery assisted by physical techniques and its potential applications in traditional Chinese medicine. J Tradit Chin Med Sci. 2021 Jul;8(3):186-97. https://doi.org/10.1016/j.jtcms.2021.07.003
Bilosomes Based Drug Delivery System. 2015;
Abdelbary AA, Abd-Elsalam WH, Al-mahallawi AM. Fabrication of novel ultradeformable bilosomes for enhanced ocular delivery of terconazole: In vitro characterization, ex vivo permeation and in vivo safety assessment. Int J Pharm. 2016 Nov;513(1-2):688-96. https://doi.org/10.1016/j.ijpharm.2016.10.006 PMid:27717916
Mohsen AM, Salama A, Kassem AA. Development of acetazolamide loaded bilosomes for improved ocular delivery: Preparation, characterization and in vivo evaluation. J Drug Deliv Sci Technol. 2020 Oct;59:101910. https://doi.org/10.1016/j.jddst.2020.101910
Tuomela A, Liu P, Puranen J, Rönkkö S, Laaksonen T, Kalesnykas G, et al. Brinzolamide nanocrystal formulations for ophthalmic delivery: Reduction of elevated intraocular pressure in vivo. Int J Pharm. 2014 Jun;467(1-2):34-41. https://doi.org/10.1016/j.ijpharm.2014.03.048 PMid:24680962
Romero GB, Keck CM, Müller RH, Bou-Chacra NA. Development of cationic nanocrystals for ocular delivery. Eur J Pharm Biopharm. 2016 Oct;107:215-22. https://doi.org/10.1016/j.ejpb.2016.07.005 PMid:27388629
Guinedi AS, Mortada ND, Mansour S, Hathout RM. Preparation and evaluation of reverse-phase evaporation and multilamellar niosomes as ophthalmic carriers of acetazolamide. Int J Pharm. 2005 Dec;306(1-2):71-82. https://doi.org/10.1016/j.ijpharm.2005.09.023 PMid:16263229
Albash R, Abdellatif MM, Hassan M, M Badawi N. Tailoring Terpesomes and Leciplex for the Effective Ocular Conveyance of Moxifloxacin Hydrochloride (Comparative Assessment): In-vitro, Ex-vivo, and In-vivo Evaluation. Int J Nanomedicine. 2021 Aug;Volume 16:5247-63. https://doi.org/10.2147/IJN.S316326 PMid:34376978
Aytekin E, Öztürk N, Vural İ, Polat HK, Çakmak HB, Çalış S, et al. Design of ocular drug delivery platforms and in vitro - in vivo evaluation of riboflavin to the cornea by non-interventional (epi-on) technique for keratoconus treatment. J Controlled Release. 2020 Aug;324:238-49. https://doi.org/10.1016/j.jconrel.2020.05.017 PMid:32413453
Published
Abstract Display: 1307 
PDF Downloads: 526 PDF Downloads: 180 How to Cite
Issue
Section
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
How to Cite
.